Organovo to Present at 2nd Annual NASH Summit
April 24 2018 - 8:05AM
Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today announced
that it will present at the 2nd Annual NASH Summit in Boston,
Ma. on Tuesday, April 24th at 4:00pm ET. Alice Chen, Director
of Tissue Applications at Organovo, will be giving a presentation
focused on the Company’s development of a 3D bioprinted human liver
tissue non-alcoholic steatohepatitis (“NASH”) model.
Event: 2nd Annual NASH
Summit Presentation Title: Modeling
NAFLD/NASH In Vitro Using 3D Bioprinted Human Liver Tissue
Date & Time: Thursday, April 24th at
4:00pm ET Location: Revere Hotel Boston
Common, Boston, Ma.
Organovo continues to develop its NASH disease
model and can now demonstrate the ability to begin with healthy
primary human cells to create a 3D bioprinted human liver tissue,
and then induce NASH phenotypes including the progressive
accumulation of fat, hepatocellular damage and fibrosis. In a
recent study, the Company evaluated the efficacy of a clinical drug
candidate being developed to treat NASH and was able to show the
reduction of key histological disease features. Today’s
presentation will show initial data on a late-stage clinical
candidate from a second major class of promising NASH drugs,
providing further evidence that Organovo’s ExVive® platform
can identify important and specific effects of NASH modulation
utilizing the ‘gold standard’ of histological imaging.
Organovo’s 3D bioprinted human liver tissues
function for at least four weeks and are comprised of a complex
multicellular architecture that more closely emulates human biology
and disease. The Company’s tissue systems have the potential to
facilitate breakthrough translational research from target
discovery to high-value drug profiling, enabling better
understanding of disease processes, discovery of novel
therapeutics, biomarkers, and the safety assessment of drugs in a
disease-relevant background.
About Organovo Holdings, Inc.
Organovo is developing and commercializing a
platform technology to produce and study living tissues that
emulate key aspects of human biology and disease for use in drug
discovery, clinical development, and therapeutic applications. The
Company develops tissue systems through internal research programs
and in collaboration with pharmaceutical, academic and other
partners. Organovo's living tissues have the potential to transform
the drug discovery process, enabling treatments to be developed
more effectively and with greater relevance to performance in human
trials and commercialization. The Company’s ExVive™ Liver and
Kidney Tissues are used in disease modeling for NASH and fibrosis,
high-value drug profiling, target and marker discovery/validation,
and other drug testing. The Company is also advancing a preclinical
program to develop its NovoTissues® liver therapeutic tissues
for critical unmet medical needs, including certain
life-threatening pediatric diseases. The Company has received
orphan designation for its potential treatment of
alpha-1-antityrpsin deficiency, its lead indication within the
category of inborn errors of metabolism. Organovo is changing the
shape of life science research and transforming medical care. Learn
more at www.organovo.com.
Forward-Looking Statements
Any statements contained in this press release that
do not describe historical facts constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations, but are subject
to a number of risks and uncertainties. Forward-looking statements
include, but are not limited to, statements regarding the potential
for one or more customer’s electing to move toward framework
agreements involving annual budgets, revenue commitments, and/or
dedicated research plans, the expected costs, timing and
operational benefits of the Company’s restructuring plan, the
financial impact of the Company’s restructuring plan on its future
operating costs and financial results, and statements regarding the
potential benefits and therapeutic uses of the Company’s
therapeutic liver tissue. The factors that could cause the
Company's actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company's ability to develop, market
and sell products and services based on its technology; the
expected benefits and efficacy of the Company's products, services
and technology; the Company’s ability to successfully complete
studies and provide the technical information required to support
market acceptance of its products, services and technology, on a
timely basis or at all; the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies, including its use of third party distributors; the
Company’s ability to recognize deferred revenue; the final results
of the Company's preclinical studies may be different from the
Company's studies or interim preclinical data results and may not
support further clinical development of its therapeutic tissues;
the Company may not successfully complete the required preclinical
and clinical trials required to obtain regulatory approval for its
therapeutic tissues on a timely basis or at all; and the Company’s
ability to meet its fiscal year 2018 outlook. These and other
factors are identified and described in more detail in the
Company's filings with the SEC, including its Annual Report on Form
10-K filed with the SEC on June 7, 2017. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that the Company may issue in the future. Except as required by
applicable law, including the securities laws of the United States,
the Company does not intend to update any of the forward-looking
statements to conform these statements to reflect actual results,
later events or circumstances or to reflect the occurrence of
unanticipated events.
Investor & Press Contact:
Steve Kunszabo
Organovo Holdings, Inc.
+1 (858) 224-1092
skunszabo@organovo.com
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Jul 2023 to Jul 2024